Other OTC - Delayed Quote USD

Pressure BioSciences, Inc. (PBIO)

0.2390 -0.0009 (-0.38%)
At close: May 17 at 3:56 PM EDT
Loading Chart for PBIO
DELL
  • Previous Close 0.2399
  • Open 0.2400
  • Bid --
  • Ask --
  • Day's Range 0.2002 - 0.2400
  • 52 Week Range 0.1400 - 1.0000
  • Volume 19,700
  • Avg. Volume 79,175
  • Market Cap (intraday) 6.152M
  • Beta (5Y Monthly) -0.18
  • PE Ratio (TTM) --
  • EPS (TTM) -1.5800
  • Earnings Date Aug 19, 2024 - Aug 23, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

www.pressurebiosciences.com

16

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PBIO

Performance Overview: PBIO

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PBIO
27.58%
S&P 500
11.18%

1-Year Return

PBIO
73.44%
S&P 500
29.04%

3-Year Return

PBIO
86.80%
S&P 500
27.06%

5-Year Return

PBIO
92.41%
S&P 500
84.38%

Compare To: PBIO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PBIO

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    6.15M

  • Enterprise Value

    27.35M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.94

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    12.03

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -212.70%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    2.27M

  • Net Income Avi to Common (ttm)

    -29.56M

  • Diluted EPS (ttm)

    -1.5800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.26k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -15.02M

Research Analysis: PBIO

Company Insights: PBIO

Research Reports: PBIO

People Also Watch